Version June 2024
| Common antigens in lymphoproliferative disorders | Cell type | Comments/use |
| CD2 | T cells | Loss marker (ie, loss of expression is suggestive of malignancy) |
| CD3 | T cells | Pan T cell marker. Expression rarely lost. |
| CD4 | T cells | T-helper and T-regulatory cells. The majority of mycosis fungoides/Sézary syndrome is CD4+. |
| CD5 | Primarily T cells | Loss marker. Expression in B cells suggestive of B-cell lymphoma/leukemia (B-CLL). |
| CD7 | T cells | Loss marker |
| CD8 | T cells | T-cytotoxic cells. Rare variants of mycosis fungoides and cytotoxic T cell lymphomas. |
| CD10 | B cells | Germinal center-derived B cells |
| CD20 | B cells | B cell marker. Does not highlight plasma cells. Target of rituximab therapy. |
| CD21 | Follicular dendritic cells | Highlights germinal centers |
| CD23 | B cells and follicular dendritic cells | Highlights germinal centers. Can be expressed in reactive B cells and B-CLL. |
| CD25 | T cells | Activated T cells and adult T cell leukemia/lymphoma (ATLL). Target of denileukin diftitox therapy. |
| CD30 | T and B cells | Activated T and B cells. CD30+ lymphoproliferative disorders. |
| CD45 | All leukocytes | Broad leukocyte marker |
| CD79a | B cells | Broader range of B cell developmental stages than CD20 (pre-B cells and most plasma cells) |
| CD138 | Plasma cells | |
| Ig light chain (lambda [λ]/kappa [Κ]) | B cells | Exclusive expression of either lambda or kappa light chain is suggestive of malignancy. Normal ratio is 3:1 kappa to lambda. |
| BCL-2 | B and T cells | Expressed by marginal zone B cells, T cells, and follicular lymphomas |
| BCL-6 | B cells | Germinal center-derived B cells |
| PAX-5 | B cells | Highlights B cells at all stages of development. Nuclear staining. |
| LMO2 | B cells | Germinal center-derived B cells |
| MUM-1 | B cells | Activated B cells. Large B cell lymphoma. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
